Oncology
Pediatric Solid Tumors
0
Pipeline Programs↗
7
Active Trials↗
1
Companies Involved↗
Pediatric Solid Tumors is an early-stage landscape with 0 programs across 1 company. The most active players are Pfizer.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
18
clinical trials
Completed5 · 28%
Recruiting4 · 22%
Withdrawn3 · 17%
Not yet recruiting2 · 11%
Terminated2 · 11%
Active, not recruiting1 · 6%
Other1 · 6%
Clinical Trials
Trial Activity
18 trials
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Recruiting·—·Phase 1·NCT04715191·24 enrolled
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Recruiting·—·Phase 1/2·NCT06721689·59 enrolled
Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)
Active, not recruiting·—·Phase 1·NCT02932956·10 enrolled
Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07444918·33 enrolled
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Completed·—·Phase 2·NCT05302921·5 enrolled
A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors
Completed·—·Phase 1·NCT00786669·13 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)